drugset

drugset / Trial / NCT06519110

Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations

NCT06519110 ↗

Phase 2 Not yet recruiting 60 enrolled Convalife (Shanghai) Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.

Timeline

Start: 2024-08-10
Primary completion: 2026-02-14
Completion: 2026-04-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Neratinib	Small molecule	240 mg	Oral

Indications